14
Participants
Start Date
June 28, 2018
Primary Completion Date
March 13, 2020
Study Completion Date
March 13, 2020
Emicizumab
Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
State University of New York at Buffalo; Women's and Children's Hospital of Buffalo, Buffalo
University of Florida, Gainesville
Indiana Hemophilia & Thrombosis center, Indianapolis
Cook Childrens Medical Center, Fort Worth
University of Utah; Division of Gastroenterology/Hepatology, Salt Lake City
Childrens Hospital of LA, Los Angeles
Stanford University/Lucile Packard Children's Hospital, Palo Alto
Newark Beth Israel Medical Center, Newark
Lead Sponsor
Genentech, Inc.
INDUSTRY